CL2007002634A1 - Uso de una composicion que comprende al menos un polipeptido que tiene actividad de peptido-1 semejante a glucagon (glp-1) como agente hipoglucemiante de larga duracion. - Google Patents

Uso de una composicion que comprende al menos un polipeptido que tiene actividad de peptido-1 semejante a glucagon (glp-1) como agente hipoglucemiante de larga duracion.

Info

Publication number: CL2007002634A1
Authority: CL; Chile
Prior art keywords: hypoglucemian; glp; glucagon; polypeptide; peptide
Prior art date: 2006-09-13

Application number

CL200702634A

Other languages

English (en)

Inventor

Mark A Matthews Jessica E Bush

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-13

Filing date

2007-09-11

Publication date

2008-05-16

2007-09-11 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2008-05-16 Publication of CL2007002634A1 publication Critical patent/CL2007002634A1/es

Links

OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 title 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title 1
102400000321 Glucagon Human genes 0.000 title 1
108060003199 Glucagon Proteins 0.000 title 1
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
101710176384 Peptide 1 Proteins 0.000 title 1
102100040918 Pro-glucagon Human genes 0.000 title 1
230000000694 effects Effects 0.000 title 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
229960004666 glucagon Drugs 0.000 title 1
230000007774 longterm Effects 0.000 title 1
229920001184 polypeptide Polymers 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CL200702634A 2006-09-13 2007-09-11 Uso de una composicion que comprende al menos un polipeptido que tiene actividad de peptido-1 semejante a glucagon (glp-1) como agente hipoglucemiante de larga duracion. CL2007002634A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82547206P	2006-09-13	2006-09-13
US86839106P	2006-12-04	2006-12-04

Publications (1)

Publication Number	Publication Date
CL2007002634A1 true CL2007002634A1 (es)	2008-05-16

Family

ID=39184534

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200702634A CL2007002634A1 (es)	2006-09-13	2007-09-11	Uso de una composicion que comprende al menos un polipeptido que tiene actividad de peptido-1 semejante a glucagon (glp-1) como agente hipoglucemiante de larga duracion.

Country Status (25)

Country	Link
US (3)	US8338369B2 (es)
EP (1)	EP2073834B1 (es)
JP (2)	JP5524620B2 (es)
KR (1)	KR101472601B1 (es)
CN (1)	CN103705911A (es)
AR (1)	AR062775A1 (es)
AU (1)	AU2007296499C1 (es)
BR (1)	BRPI0716765A8 (es)
CA (1)	CA2662622C (es)
CL (1)	CL2007002634A1 (es)
CR (1)	CR10684A (es)
EA (1)	EA017159B1 (es)
ES (1)	ES2442869T3 (es)
IL (1)	IL197448A (es)
JO (1)	JO2945B1 (es)
MA (1)	MA30768B1 (es)
MX (1)	MX2009002863A (es)
MY (1)	MY149911A (es)
NO (1)	NO20091266L (es)
NZ (1)	NZ575419A (es)
PE (2)	PE20080840A1 (es)
SG (2)	SG10201501749WA (es)
TW (1)	TWI430806B (es)
WO (1)	WO2008033888A2 (es)
ZA (1)	ZA200901548B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20160866T1 (hr)	2005-11-04	2016-10-07	Glaxosmithkline Llc	Postupci primjene hipoglikemijskih sredstava
SI2373681T1 (sl) *	2008-12-10	2017-05-31	Glaxosmithkline Llc Corporation Service Company	Farmacevtski sestavki albiglutida
JP2013525491A (ja) *	2010-05-04	2013-06-20	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	心血管障害を治療または予防し心血管保護を提供する方法
HRP20180425T1 (hr)	2010-12-16	2018-04-20	Novo Nordisk A/S	Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
BR112013026195A2 (pt)	2011-04-12	2016-11-29	Novo Nordisk As	derivados de glp-1 duplamente acilados
PT2827845T (pt)	2012-03-22	2019-03-29	Novo Nordisk As	Composições compreendendo um agente de entrega e sua preparação
SMT201800491T1 (it)	2012-03-22	2018-11-09	Novo Nordisk As	Composizioni di peptidi glp-1 e relativa preparazione
JP6517690B2 (ja)	2012-06-20	2019-05-22	ノヴォノルディスクアー／エス	ペプチド及び送達剤を含む錠剤製剤
ES2688462T3 (es) *	2013-05-02	2018-11-02	Novo Nordisk A/S	Dosificación oral de compuestos de GLP-1
WO2014192284A1 (en)	2013-05-28	2014-12-04	Takeda Pharmaceutical Company Limited	Peptide compound
US10501516B2 (en)	2016-05-24	2019-12-10	Takeda Pharmaceutical Company Limited	Peptide compound
EP3746111B1 (en)	2018-02-02	2023-07-19	Novo Nordisk A/S	Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
TWI837615B (zh) *	2021-03-23	2024-04-01	美商美國禮來大藥廠	含腸促胰島素(incretin)類似物之組合物及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5545618A (en) *	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
WO1998005351A1 (en)	1996-08-08	1998-02-12	Amylin Pharmaceuticals, Inc.	Methods for regulating gastrointestinal motility
US6277819B1 (en) *	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
US6380357B2 (en)	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
IL141241A0 (en) *	1998-08-28	2002-03-10	Lilly Co Eli	Method for administering insulinotropic peptides
CN1191273C (zh) *	1999-05-17	2005-03-02	康久化学公司	长效促胰岛肽
US6395767B2 (en) *	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
EP1355942B1 (en) *	2000-12-07	2008-08-27	Eli Lilly And Company	Glp-1 fusion proteins
US7259233B2 (en)	2000-12-13	2007-08-21	Eli Lilly And Company	Chronic treatment regimen using glucagon-like insulinotropic peptides
JP2005506956A (ja) *	2001-06-01	2005-03-10	イーライ・リリー・アンド・カンパニー	長時間作用性ｇｌｐ−１製剤
IL160493A0 (en) *	2001-08-23	2004-07-25	Lilly Co Eli	Glucagon-like peptide-1 analogs
AR036711A1 (es)	2001-10-05	2004-09-29	Bayer Corp	Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
RU2353625C2 (ru)	2001-10-18	2009-04-27	Бристол-Маерс Сквибб Компани	Миметики человеческого глюканоподобного пептида-1 и их применение в лечении диабета и родственных состояний
CA2484556A1 (en)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin fusion proteins
EP2990417A1 (en)	2001-12-21	2016-03-02	Human Genome Sciences, Inc.	Albumin insulin fusion protein
JP4282485B2 (ja) *	2002-01-08	2009-06-24	イーライリリーアンドカンパニー	伸長グルカゴン様ペプチド−１アナログ
EP1594530A4 (en)	2003-01-22	2006-10-11	Human Genome Sciences Inc	HYBRID PROTEINS OF ALBUMIN
AR046778A1 (es) *	2003-11-12	2005-12-21	Phenomix Corp	Compuestos heterociclicos de acido boronico. metodos de obtencion y composiciones farmaceuticas.
BRPI0506781B1 (pt) *	2004-01-13	2015-06-02	Asahi Glass Co Ltd	Laminado de multicamadas e método de produção do mesmo
AU2005211725B2 (en)	2004-02-09	2010-07-15	Human Genome Sciences, Inc.	Albumin fusion proteins
EP2316446A1 (en) *	2004-06-11	2011-05-04	Novo Nordisk A/S	Counteracting drug-induced obesity using GLP-1 agonists
HRP20160866T1 (hr) *	2005-11-04	2016-10-07	Glaxosmithkline Llc	Postupci primjene hipoglikemijskih sredstava
WO2007139589A1 (en)	2006-05-26	2007-12-06	Bristol-Myers Squibb Company	Sustained release glp-1 receptor modulators

2007
- 2007-09-11 JO JO2007382A patent/JO2945B1/en active
- 2007-09-11 CL CL200702634A patent/CL2007002634A1/es unknown
- 2007-09-11 TW TW096133808A patent/TWI430806B/zh not_active IP Right Cessation
- 2007-09-11 PE PE2007001215A patent/PE20080840A1/es not_active Application Discontinuation
- 2007-09-11 PE PE2012001061A patent/PE20121528A1/es not_active Application Discontinuation
- 2007-09-12 EP EP07842306.8A patent/EP2073834B1/en active Active
- 2007-09-12 US US12/441,152 patent/US8338369B2/en not_active Expired - Fee Related
- 2007-09-12 WO PCT/US2007/078226 patent/WO2008033888A2/en not_active Ceased
- 2007-09-12 AU AU2007296499A patent/AU2007296499C1/en not_active Ceased
- 2007-09-12 EA EA200970274A patent/EA017159B1/ru not_active IP Right Cessation
- 2007-09-12 MX MX2009002863A patent/MX2009002863A/es active IP Right Grant
- 2007-09-12 AR ARP070104049A patent/AR062775A1/es not_active Application Discontinuation
- 2007-09-12 CN CN201410014248.3A patent/CN103705911A/zh active Pending
- 2007-09-12 KR KR1020097007414A patent/KR101472601B1/ko not_active Expired - Fee Related
- 2007-09-12 BR BRPI0716765A patent/BRPI0716765A8/pt not_active Application Discontinuation
- 2007-09-12 NZ NZ575419A patent/NZ575419A/en not_active IP Right Cessation
- 2007-09-12 ES ES07842306.8T patent/ES2442869T3/es active Active
- 2007-09-12 MY MYPI20090993A patent/MY149911A/en unknown
- 2007-09-12 SG SG10201501749WA patent/SG10201501749WA/en unknown
- 2007-09-12 CA CA2662622A patent/CA2662622C/en not_active Expired - Fee Related
- 2007-09-12 JP JP2009528440A patent/JP5524620B2/ja active Active
- 2007-09-12 SG SG2011063856A patent/SG174770A1/en unknown
2009
- 2009-03-04 ZA ZA2009/01548A patent/ZA200901548B/en unknown
- 2009-03-05 IL IL197448A patent/IL197448A/en active IP Right Grant
- 2009-03-23 CR CR10684A patent/CR10684A/es not_active Application Discontinuation
- 2009-03-26 NO NO20091266A patent/NO20091266L/no not_active Application Discontinuation
- 2009-03-30 MA MA31741A patent/MA30768B1/fr unknown
2012
- 2012-06-12 US US13/494,253 patent/US20130005652A1/en not_active Abandoned
2013
- 2013-07-19 US US13/946,296 patent/US20140066371A1/en not_active Abandoned
2014
- 2014-04-10 JP JP2014081275A patent/JP5753924B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN103705911A (zh)	2014-04-09
EP2073834A4 (en)	2010-11-03
EA017159B1 (ru)	2012-10-30
EP2073834A2 (en)	2009-07-01
IL197448A (en)	2013-06-27
IL197448A0 (en)	2011-08-01
JP5524620B2 (ja)	2014-06-18
TWI430806B (zh)	2014-03-21
WO2008033888A2 (en)	2008-03-20
JP2014148524A (ja)	2014-08-21
JP5753924B2 (ja)	2015-07-22
AU2007296499B2 (en)	2013-05-02
WO2008033888A3 (en)	2008-10-16
KR101472601B1 (ko)	2014-12-15
TW200824706A (en)	2008-06-16
MA30768B1 (fr)	2009-10-01
JO2945B1 (en)	2016-03-15
BRPI0716765A2 (pt)	2013-09-24
SG10201501749WA (en)	2015-05-28
US8338369B2 (en)	2012-12-25
NZ575419A (en)	2011-11-25
PE20080840A1 (es)	2008-08-27
AU2007296499C1 (en)	2013-09-12
CA2662622C (en)	2017-01-17
MX2009002863A (es)	2009-03-30
JP2010503697A (ja)	2010-02-04
AR062775A1 (es)	2008-12-03
EP2073834B1 (en)	2013-10-23
CA2662622A1 (en)	2008-03-20
BRPI0716765A8 (pt)	2017-02-21
SG174770A1 (en)	2011-10-28
NO20091266L (no)	2009-06-09
US20140066371A1 (en)	2014-03-06
AU2007296499A1 (en)	2008-03-20
ZA200901548B (en)	2010-02-24
PE20121528A1 (es)	2012-12-12
ES2442869T3 (es)	2014-02-14
EA200970274A1 (ru)	2009-08-28
MY149911A (en)	2013-10-31
US20100009910A1 (en)	2010-01-14
KR20090059155A (ko)	2009-06-10
US20130005652A1 (en)	2013-01-03
CR10684A (es)	2009-04-28

Publication	Publication Date	Title
CL2007002634A1 (es)	2008-05-16	Uso de una composicion que comprende al menos un polipeptido que tiene actividad de peptido-1 semejante a glucagon (glp-1) como agente hipoglucemiante de larga duracion.
BRPI0920881A2 (pt)	2017-09-26	medicamento compreendendo combinação de uma insulina e um agonista de glp-1, processo para fabricação, bem como uso do mesmo kit.
CL2014000024A1 (es)	2014-11-21	Composición que comprende un polipéptido quimérico que tiene actividad de factor viii, y uso de la composición para prevenir, disminuir o tratar una afección de sangrado, tal como hemofilia.
UY32764A (es)	2011-01-31	Preparaciones insulinicas que comprenden metionina
CL2008003243A1 (es)	2009-02-27	Compuesto que exhibe actividad antagonista del glucagon y actividad agonista del peptido-1 tipo glucagon (glp); composicion farmaceutica y kit que lo comprende; y su uso para tratar hiperglucemia.
BRPI0814593A2 (pt)	2015-01-20	Composto, composição farmacêutica que o contém e uso do composto.
CL2013001104A1 (es)	2013-08-23	Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras.
BRPI0806531A2 (pt)	2014-04-22	Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
BRPI1008906A2 (pt)	2016-03-15	composto, composição farmacêutica, e, uso de um composto.
CO6541565A2 (es)	2012-10-16	Composición famacéutica que comprende un agonista de glp-1, una insulina y metionina
BRPI0913264A2 (pt)	2016-01-26	copoliamida, composição compreendendo tal copoliamida e seu uso
CL2007003552A1 (es)	2008-07-18	Compuestos derivados de pirimidina y piridina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno proliferativo celular.
BRPI0907663A8 (pt)	2018-08-07	composição que compreende hfo- 123 yf, composição que compreende hcfc-243db, composição que compreende hcfo- 1233xf, composição que comproeende hcfc- 244bb, uso das composições e método de uso das composições
CL2007002377A1 (es)	2008-04-04	Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno.
BRPI0911333A2 (pt)	2015-10-06	composições de limpeza que incorporam solventes verdes e métodos de uso.
CL2008000791A1 (es)	2008-05-30	Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm
DK1919878T3 (da)	2010-10-25	Pyridazinonderivater som thyroidhormonreceptoragonister
BRPI0913216A2 (pt)	2016-01-19	uso de um herpesvírus recombinante de perus, e, herpesvírus recombinante de perus.
BRPI0719523A2 (pt)	2015-06-16	Derivado de espirocetal de tioglicose e uso deste como agente terapêutico para diabetes
DOP2011000346A (es)	2012-01-15	Composiciones adyuvantes que comprende un agente de isotonicidad no-ionico
EA201200484A1 (ru)	2012-12-28	Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
AR059444A1 (es)	2008-04-09	Composiciones ramnolipidicas y metodos de uso relacionados
BRPI0716698A2 (pt)	2014-02-25	Composto, composição farmacêutica e uso de um composto
BRPI0906937A2 (pt)	2016-04-19	composto, composição farmacêutica, e, uso de um composto
DK2333056T3 (da)	2014-08-04	Væskeformig sammensætning, der omfatter en asparaginprotease